Last reviewed · How we verify
R-mNHL-BFM-90 + auto-SCT
R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue.
R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue. Used for Relapsed or refractory non-Hodgkin lymphoma (B-cell).
At a glance
| Generic name | R-mNHL-BFM-90 + auto-SCT |
|---|---|
| Sponsor | National Research Center for Hematology, Russia |
| Drug class | Rituximab-based chemotherapy regimen with autologous stem cell transplantation |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a multimodal approach combining rituximab (anti-CD20 monoclonal antibody) with the BFM-90 chemotherapy backbone (typically including cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by autologous stem cell transplantation (auto-SCT). The rituximab targets CD20 antigen on malignant B cells, while the chemotherapy provides cytotoxic effects, and auto-SCT allows delivery of higher chemotherapy doses with hematopoietic recovery.
Approved indications
- Relapsed or refractory non-Hodgkin lymphoma (B-cell)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Mucositis
- Nausea/vomiting
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-mNHL-BFM-90 + auto-SCT CI brief — competitive landscape report
- R-mNHL-BFM-90 + auto-SCT updates RSS · CI watch RSS
- National Research Center for Hematology, Russia portfolio CI